AstraZeneca PLC (AZN)vsEchoStar Corporation (SATS)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
SATS
EchoStar Corporation
$127.15
+3.69%
COMMUNICATION SERVICES · Cap: $36.44B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 303% more annual revenue ($60.44B vs $15.00B). AZN leads profitability with a 17.2% profit margin vs -96.6%. SATS appears more attractively valued with a PEG of 1.34. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
SATS
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+66.0%
Fair Value
$323.23
Current Price
$127.15
$196.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
ROE of -111.3% — below average capital efficiency
Revenue declined 4.3%
Earnings declined 85.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SATS
PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : SATS
The primary concerns for SATS are Piotroski F-Score, Return on Equity, Revenue Growth. Debt-to-equity of 4.40 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while SATS is a turnaround play — different risk/reward profiles.
SATS carries more volatility with a beta of 0.96 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 34/100), backed by strong 17.2% margins and 12.5% revenue growth. SATS offers better value entry with a 66.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
EchoStar Corporation
COMMUNICATION SERVICES · TELECOM SERVICES · USA
EchoStar Corporation provides broadband satellite technologies and broadband Internet services. The company is headquartered in Englewood, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?